JP7607590B2 - 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト - Google Patents
異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト Download PDFInfo
- Publication number
- JP7607590B2 JP7607590B2 JP2021569042A JP2021569042A JP7607590B2 JP 7607590 B2 JP7607590 B2 JP 7607590B2 JP 2021569042 A JP2021569042 A JP 2021569042A JP 2021569042 A JP2021569042 A JP 2021569042A JP 7607590 B2 JP7607590 B2 JP 7607590B2
- Authority
- JP
- Japan
- Prior art keywords
- complement
- antibody
- domain
- cells
- mmn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6408—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21043—Classical-complement-pathway C3/C5 convertase (3.4.21.43)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024220534A JP2025038109A (ja) | 2019-05-21 | 2024-12-17 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024221343A JP2025041724A (ja) | 2019-05-21 | 2024-12-18 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1907153.9A GB2584105B (en) | 2019-05-21 | 2019-05-21 | Methods of treating neuropathy |
| GB1907153.9 | 2019-05-21 | ||
| PCT/EP2020/064234 WO2020234432A1 (en) | 2019-05-21 | 2020-05-21 | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024220534A Division JP2025038109A (ja) | 2019-05-21 | 2024-12-17 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024221343A Division JP2025041724A (ja) | 2019-05-21 | 2024-12-18 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533705A JP2022533705A (ja) | 2022-07-25 |
| JP2022533705A5 JP2022533705A5 (cg-RX-API-DMAC7.html) | 2023-05-31 |
| JP7607590B2 true JP7607590B2 (ja) | 2024-12-27 |
Family
ID=67385155
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569042A Active JP7607590B2 (ja) | 2019-05-21 | 2020-05-21 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024220534A Pending JP2025038109A (ja) | 2019-05-21 | 2024-12-17 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024221343A Pending JP2025041724A (ja) | 2019-05-21 | 2024-12-18 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024220534A Pending JP2025038109A (ja) | 2019-05-21 | 2024-12-17 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024221343A Pending JP2025041724A (ja) | 2019-05-21 | 2024-12-18 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Country Status (21)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3893924T3 (pl) * | 2018-12-13 | 2025-01-13 | argenx BV | Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania |
| CN117597353A (zh) * | 2021-03-18 | 2024-02-23 | 艾菲洛之克公司 | 抗因子c3的sac7d变体及其治疗补体介导疾患的医疗用途 |
| EP4308591A4 (en) * | 2021-03-18 | 2025-04-02 | Affilogic | POLYPEPTIDES FOR COMPLEMENT INHIBITION |
| EP4059949A1 (en) * | 2021-03-18 | 2022-09-21 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
| US20240166692A1 (en) * | 2021-03-18 | 2024-05-23 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
| MX2024008273A (es) * | 2021-12-30 | 2024-07-19 | Annexon Inc | Composiciones y metodos para el tratamiento de la enfermedad de huntington. |
| MA71448A (fr) * | 2022-07-14 | 2025-04-30 | argenx BV | Régimes posologiques pour le traitement d'une neuropathie motrice multifocale (nmm) |
| EP4676952A2 (en) * | 2023-03-07 | 2026-01-14 | The Cleveland Clinic Foundation | Human complement component 2 binding molecules |
| WO2025146509A1 (en) * | 2024-01-05 | 2025-07-10 | argenx BV | Methods of treating multifocal motor neuropathy (mmn) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110104156A1 (en) | 2003-09-11 | 2011-05-05 | Premkumar Christadoss | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| JP2016520313A (ja) | 2013-05-23 | 2016-07-14 | ブロテイオ ファーマ ビーヴィBroteio Pharma B.V. | ヒト補体因子c2に結合する結合分子、及び、その使用。 |
| WO2019089922A1 (en) | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| WO2008030505A2 (en) * | 2006-09-05 | 2008-03-13 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| LT3028716T (lt) * | 2006-10-10 | 2020-12-10 | Regenesance B.V. | Komplemento slopinimas nervų regeneracijos pagerinimui |
| JP6223659B2 (ja) * | 2008-11-10 | 2017-11-01 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 補体関連障害を処置するための方法および組成物 |
| WO2010056399A1 (en) * | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| PL2753636T3 (pl) * | 2011-09-07 | 2020-05-18 | The Trustees Of The University Of Pennsylvania | Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych |
| CN102949719A (zh) * | 2012-04-28 | 2013-03-06 | 上海市徐汇区中心医院 | 静脉注射免疫球蛋白抑制霍乱毒素和半乳糖凝集素-1结合到神经节苷脂gm1 |
| WO2014096958A1 (en) * | 2012-11-02 | 2014-06-26 | Academisch Medisch Centrum | Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders |
| EP2997045A4 (en) * | 2013-05-15 | 2016-11-23 | Annexon Inc | ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF |
| WO2015089368A2 (en) * | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
| PL3215527T3 (pl) * | 2014-11-05 | 2025-04-28 | Annexon, Inc. | Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie |
| CN108026134A (zh) * | 2015-09-16 | 2018-05-11 | 巴塞尔大学 | 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体 |
| FI3380518T3 (fi) * | 2015-11-24 | 2026-05-29 | Annexon Inc | Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä |
| WO2017196960A1 (en) * | 2016-05-10 | 2017-11-16 | Annexon, Inc. | Anti-complement factor c4/c4b antibodies and uses thereof |
| SG11201907583TA (en) * | 2017-03-14 | 2019-09-27 | Bioverativ Usa Inc | Methods for treating complement-mediated diseases and disorders |
| PL3893924T3 (pl) * | 2018-12-13 | 2025-01-13 | argenx BV | Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania |
-
2019
- 2019-05-21 GB GB1907153.9A patent/GB2584105B/en active Active
-
2020
- 2020-05-21 BR BR112021023198A patent/BR112021023198A2/pt unknown
- 2020-05-21 CA CA3138401A patent/CA3138401A1/en active Pending
- 2020-05-21 AU AU2020279543A patent/AU2020279543B2/en active Active
- 2020-05-21 HU HUE20729653A patent/HUE072743T2/hu unknown
- 2020-05-21 CN CN202080037596.6A patent/CN114269382B/zh active Active
- 2020-05-21 DK DK20729653.4T patent/DK3972643T3/da active
- 2020-05-21 MA MA71752A patent/MA71752A/fr unknown
- 2020-05-21 PL PL20729653.4T patent/PL3972643T3/pl unknown
- 2020-05-21 EA EA202193189A patent/EA202193189A1/ru unknown
- 2020-05-21 FI FIEP20729653.4T patent/FI3972643T3/fi active
- 2020-05-21 JP JP2021569042A patent/JP7607590B2/ja active Active
- 2020-05-21 EP EP25159620.1A patent/EP4570316A3/en active Pending
- 2020-05-21 PT PT207296534T patent/PT3972643T/pt unknown
- 2020-05-21 CN CN202410047987.6A patent/CN118021970A/zh active Pending
- 2020-05-21 MX MX2021014170A patent/MX2021014170A/es unknown
- 2020-05-21 EP EP20729653.4A patent/EP3972643B1/en active Active
- 2020-05-21 SG SG11202112232YA patent/SG11202112232YA/en unknown
- 2020-05-21 ES ES20729653T patent/ES3035736T3/es active Active
- 2020-05-21 KR KR1020217039139A patent/KR20220010505A/ko active Pending
- 2020-05-21 LT LTEPPCT/EP2020/064234T patent/LT3972643T/lt unknown
- 2020-05-21 WO PCT/EP2020/064234 patent/WO2020234432A1/en not_active Ceased
-
2021
- 2021-11-11 IL IL288010A patent/IL288010A/en unknown
- 2021-11-18 MX MX2025014486A patent/MX2025014486A/es unknown
-
2024
- 2024-12-17 JP JP2024220534A patent/JP2025038109A/ja active Pending
- 2024-12-18 JP JP2024221343A patent/JP2025041724A/ja active Pending
-
2026
- 2026-07-01 AU AU2026205212A patent/AU2026205212A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110104156A1 (en) | 2003-09-11 | 2011-05-05 | Premkumar Christadoss | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| JP2016520313A (ja) | 2013-05-23 | 2016-07-14 | ブロテイオ ファーマ ビーヴィBroteio Pharma B.V. | ヒト補体因子c2に結合する結合分子、及び、その使用。 |
| WO2019089922A1 (en) | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
Non-Patent Citations (5)
| Title |
|---|
| ACTA NEUROPATHOLOGICA COMMUNICATIONS,2016年03月02日,VOL:4, NR:23,PAGE(S):1-16 |
| ANONYMOUS,ARGENX ANNOUNCES EXPANSION OF ITS PIPELINE WITH ADDITION OF COMPLEMENT-TARGETED 以下備考,[ONLINE],2018年03月22日,PAGE(S):1-3,https://www.globenewswire.com/news-release/2018/03/22/1444011/0/en/argenx-announces-expansion-of-its-pipeline-with-addition-of-complement-targeted-ARGX-117-for-treatment-of-severe-autoimmune-diseases.html?print=1,ARGX-117 FOR TREATMENT OF SEVERE AUTOIMMUNE DISEASES |
| CLINICAL IMMUNOLOGY,2015年09月,VOL:161, NR:2,PAGE(S):225-240 |
| JOURNAL OF NEUROIMMUNOLOGY,2008年12月15日,VOL:205, NR:1-2,PAGE(S):101-104 |
| JOURNAL OF NEUROIMMUNOLOGY,2010年12月15日,VOL:229, NR:1-2,PAGE(S):256-262 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025038109A (ja) | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト | |
| US20240343830A1 (en) | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | |
| US20240293465A1 (en) | Methods for Treating and/or Preventing Graft-Versus-Host Disease and/or Diffuse Alveolar Hemorrhage and/or Veno-Occlusive Disease Associated with Hematopoietic Stem Cell Transplant | |
| US10723788B2 (en) | Anti-complement factor C1q Fab fragments and uses thereof | |
| JP6672533B1 (ja) | C5関連疾患の治療または予防用の医薬組成物およびc5関連疾患を治療または予防するための方法 | |
| CN110167961A (zh) | 用于治疗或预防c5相关疾病的药物组合物和治疗或预防c5相关疾病的方法 | |
| JP7499760B2 (ja) | 脳損傷を治療するための組成物及び方法 | |
| RS61351B1 (sr) | Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2 | |
| AU2017299579A1 (en) | Compositions and methods for treating frontotemporal dementia | |
| CN107074939B (zh) | H因子增强抗体及其用途 | |
| KR20250114942A (ko) | 보체-매개 질환의 치료에 사용하기 위한 인자 h에 융합된 항-c5 항체 | |
| HK40105187A (en) | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies | |
| EA048122B1 (ru) | Способы лечения нейропатий | |
| HK40063067A (en) | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies | |
| HK40063067B (en) | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies | |
| HK40062141A (en) | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies | |
| HK40062141B (en) | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies | |
| HK40039717A (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| EA046178B1 (ru) | Способы лечения и/или предотвращения реакции трансплантат против хозяина и/или диффузного альвеолярного кровотечения, и/или веноокклюзионной болезни, связанных с трансплантатом гемопоэтических стволовых клеток | |
| BR112018009311B1 (pt) | Uso de uma composição compreendendo uma quantidade de um anticorpo inibidor de masp-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220311 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230519 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230519 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240423 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240719 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240830 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241126 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241217 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7607590 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |